Day 3 of the course started on anti-malaria drugs. We discussed who should take them and some of their effects, what they should be used for ( treatment? Prevention?) and against what (just Pf? Pf and Pv? All parasites?). The most heated debates arose when the issue of resistance came about. Someone mentioned resistance to artemisinin and immediately some voices rose to say that that is still not a given. There are indeed reported cases of treatment that had to be extended but not of treatment failure as such, which means that, real resistance is still not fixed in the parasite population.
I have just arrived (about 4 days ago) from a leadership course held at the Harvard Business School entitled Malaria: Science of Eradication. This course is a joint effort by Dr Dyann Wirth, Dr Pedro Alonso and Dr Marcel Tanner and is intended to be the first of many. The next course has already been allocated to Barcelona, home of Dr Pedro Alonso's ISGlobal.